Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that David M. Epstein, Ph.D., President and CEO, will present at the Jefferies 2020 Virtual London Healthcare Conference. The event occurs on November 18, 2020, at 2:40 PM GMT/9:40 AM ET. The presentation will focus on the company's progress in developing precision oncology therapies targeting genetically defined cancers.

A live webcast is accessible via their investor relations page, with a replay available for three weeks post-event.

CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 2:40 PM GMT/9:40 AM ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com

FAQ

What is the date and time of Black Diamond Therapeutics' presentation at the Jefferies 2020 Virtual London Healthcare Conference?

The presentation will take place on November 18, 2020, at 2:40 PM GMT/9:40 AM ET.

Who will present for Black Diamond Therapeutics at the Jefferies 2020 Virtual London Healthcare Conference?

David M. Epstein, Ph.D., the President and CEO, will present the update.

How can I access the live webcast of Black Diamond Therapeutics' presentation?

The live webcast can be accessed through the investor relations section of Black Diamond Therapeutics' website.

Will there be a replay of the presentation from the Jefferies 2020 Virtual London Healthcare Conference?

Yes, a replay will be available for three weeks after the event.

What innovations does Black Diamond Therapeutics focus on?

Black Diamond Therapeutics is focused on precision oncology medicine, developing small molecule, tumor-agnostic therapies targeting genetically defined cancers.

What is the stock symbol for Black Diamond Therapeutics?

The stock symbol for Black Diamond Therapeutics is BDTX.